GOOD WEEK

Willdan Group, Inc.

WLDN+29.3% Shares shot up following strong third Quarter results. Willdan was also awarded an $11 million contract with Azusa Unified School District.  Willdan Group, Inc., together with its subsidiaries, provides professional, technical and consulting services primarily in the United States. It operates in two segments, Energy, and Engineering and Consulting. The Energy segment offers comprehensive audit and surveys, program design, master planning, demand reduction, grid optimization, benchmarking analyses, design engineering, construction management, performance contracting, installation, alternative financing, and measurement and verification services, as well as software and data analytics.

Shares of Peak Bio, Inc.

PKBO +105.8% got a boost, shooting up as Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.

aging has often appeared inconsistent with that guidance.

BAD WEEK

Funko, Inc. FNKO -59.4% Shares tumbled after the company reported worse-than-expected results.  Funko, Inc., a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, Europe, and internationally. The company provides vinyl, blind-packed miniature, and action figures; fashion accessories, including bags, backpacks, and wallets; apparel, such as t-shirts and hats; board games, plush products, and accessories, such as keychains, pens, and pins; homewares, comprising drinkware, and other home accessories, non-fungible tokens, and others.

Shares Pulmonx Corporation LUNG -60.9% were down after the company reported worse-than-expected Q3 sales results.  Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

WHAT ELSE HAPPENED?

The U.S. economy added 261,000 jobs in October, while September's reading was upwardly revised from previously reported. The unemployment rate ticked up to 3.7%.

Investors have bet that some signs of a cooling labor market would force the Federal Reserve to scale back on its aggressive rate-hiking campaign, slight moderations in the data may not be enough for a pause on increases, with labor conditions still historically tight.

Although job vacancies have moved below their highs and the pace of job gains, the labor market continues to be out of balance, with demand substantially exceeding the supply of available workers, the U.S. central bank delivered a fourth straight interest rate hike of 75 basis points.

GET IN ON THE ACTION

If you are interested in opening a trading account with CSB and getting in on the winners, enquire with one of our friendly Banking officer or get started online by setting up an account today.